What is the recommended approach to evaluating and managing a patient with retiform purpura?

Approach to Retiform Purpura

Retiform purpura represents complete vascular occlusion requiring immediate recognition and systematic evaluation to identify life-threatening causes including vasculitis, thrombotic disorders, sepsis, and calciphylaxis—conditions that carry significant morbidity and mortality if treatment is delayed. 1, 2

Immediate Recognition and Clinical Assessment

Retiform purpura presents as branching, net-like purpuric lesions that reflect complete blockage of dermal and subcutaneous blood flow, distinguishing it from simple petechiae or ecchymoses. 1, 2

Key clinical features to document immediately:

• Distribution pattern: Distal extremities suggest embolic phenomena or vasculitis; truncal involvement suggests warfarin/heparin necrosis or calciphylaxis 1, 3
• Palpability: Palpable purpuric plaques indicate vascular inflammation (vasculitis, calciphylaxis, warfarin necrosis, antiphospholipid syndrome, heparin necrosis) 3
• Associated skin findings: Livedo reticularis, livedo racemosa, necrosis, or ulceration suggest hypercoagulability 4
• Pain severity: Severe pain out of proportion to examination suggests calciphylaxis or ischemia 5
• Systemic symptoms: Fever, hypotension, or altered mental status suggest septic emboli or disseminated intravascular coagulation (DIC) 1, 6

Critical history elements:

• Recent medication changes (warfarin initiation within 3-7 days, heparin exposure) 1, 3
• Chronic kidney disease or dialysis (calciphylaxis risk) 5
• Autoimmune disease history (antiphospholipid syndrome, vasculitis) 1
• Recent infection or COVID-19 (thrombotic complications) 7
• Hypercoagulable state risk factors (malignancy, pregnancy, thrombosis history) 4

Diagnostic Algorithm by Clinical Presentation

Step 1: Obtain Skin Biopsy Immediately

A punch biopsy extending into subcutaneous fat is mandatory and should not be delayed. 8 The biopsy provides definitive evidence of vasculitis versus thrombosis and guides treatment urgency. 8, 1

• Biopsy technique: Two 4-6mm punch biopsies from the edge of active lesions, including subcutaneous fat 1, 3
• Send for: Routine histology, direct immunofluorescence, and tissue culture if infection suspected 1, 2

Step 2: Initial Laboratory Workup (Obtain Within 24 Hours)

Tier 1 - Immediate labs (order stat):

• Complete blood count with differential and peripheral smear (evaluate for thrombocytopenia, schistocytes suggesting DIC or thrombotic microangiopathy) 9, 1
• Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer (screen for DIC) 10, 1
• Comprehensive metabolic panel including creatinine (assess renal involvement in vasculitis or calciphylaxis) 8, 5
• Blood cultures if febrile (rule out septic emboli) 1, 6

Tier 2 - Send same day but results guide subsequent management:

• Antineutrophil cytoplasmic antibody (ANCA) with MPO and PR3 specificity (granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis) 8
• Antiphospholipid antibodies: lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-glycoprotein I IgG/IgM 1, 4
• Cryoglobulins (cryoglobulinemic vasculitis) 1
• Complement C3, C4, CH50 (complement-mediated vasculitis) 8
• Protein C, protein S, antithrombin III levels (if no warfarin/heparin exposure and hypercoagulability suspected) 1, 4

Do NOT order indiscriminately: Ordering hypercoagulability panels during acute illness or anticoagulation therapy produces false-positive results and complicates interpretation. 4

Step 3: Risk-Stratify by Most Likely Diagnosis

If palpable purpuric plaques + acute presentation:

1. Warfarin necrosis (if warfarin started 3-7 days prior): Stop warfarin immediately, give vitamin K 10mg IV, fresh frozen plasma, and initiate heparin bridging 1, 3
2. Heparin necrosis (if heparin exposure): Stop all heparin products immediately, check platelet count and HIT antibodies, consider direct thrombin inhibitor 1, 3
3. Calciphylaxis (if chronic kidney disease/dialysis + severe pain): Urgent wound care, sodium thiosulfate 25g IV three times weekly, stop warfarin and vitamin D analogs, optimize calcium-phosphate balance 3, 5
4. Catastrophic antiphospholipid syndrome (if multiorgan involvement + positive antiphospholipid antibodies): Anticoagulation with heparin, high-dose corticosteroids (methylprednisolone 1g IV daily × 3 days), plasma exchange, consider rituximab 6

If systemic symptoms + fever:

1. Septic emboli (bacterial/fungal): Broad-spectrum antibiotics immediately (vancomycin + piperacillin-tazobactam or meropenem), echocardiogram to evaluate for endocarditis 1, 6
2. DIC: Treat underlying cause, supportive care with fresh frozen plasma and cryoprecipitate as needed, avoid platelet transfusion unless active bleeding 1, 6

If ANCA-positive or biopsy shows vasculitis:

1. ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis): Glucocorticoids (methylprednisolone 1g IV daily × 3 days or prednisone 1mg/kg/day) PLUS rituximab 375mg/m² weekly × 4 weeks OR cyclophosphamide 15mg/kg IV every 2 weeks 8
2. Consider plasma exchange if serum creatinine ≥500 µmol/L (5.7 mg/dL) due to rapidly progressive glomerulonephritis 8
3. Refer immediately to vasculitis center of expertise for refractory or life-threatening disease 8

Treatment Principles by Etiology

Vasculitis (ANCA-Associated)

For organ-threatening or life-threatening disease, initiate remission-induction therapy immediately with glucocorticoids PLUS either rituximab OR cyclophosphamide. 8

• Glucocorticoid regimen: Methylprednisolone 1g IV daily × 3 days, then prednisone 1mg/kg/day with rapid taper 8
• Rituximab: 375mg/m² IV weekly × 4 weeks (preferred for relapsing disease or cyclophosphamide contraindication) 8
• Cyclophosphamide: 15mg/kg IV every 2 weeks (alternative to rituximab) 8
• Plasma exchange: Add if creatinine ≥500 µmol/L or severe diffuse alveolar hemorrhage 8

Maintenance therapy after remission: Rituximab is preferred over azathioprine or methotrexate for sustained remission (continue ≥24 months). 8

Thrombotic Disorders

Anticoagulation is the cornerstone for most thrombotic causes, but specific antidotes are required for drug-induced necrosis:

• Warfarin necrosis: Vitamin K 10mg IV, fresh frozen plasma 10-15 mL/kg, heparin bridging 1
• Heparin necrosis/HIT: Stop all heparin, use direct thrombin inhibitor (argatroban or bivalirudin) 1
• Antiphospholipid syndrome: Therapeutic anticoagulation with heparin (target aPTT 1.5-2.5× control or anti-Xa 0.3-0.7), transition to warfarin (target INR 2-3) 1
• Protein C/S deficiency: Heparin bridging during warfarin initiation to prevent paradoxical thrombosis 1

Calciphylaxis

Multidisciplinary approach with wound care, sodium thiosulfate, and elimination of risk factors: 5

• Sodium thiosulfate 25g IV three times weekly during dialysis 5
• Stop warfarin and vitamin D analogs immediately 5
• Optimize calcium-phosphate product (<55 mg²/dL²) 5
• Aggressive wound care with non-adherent dressings 5
• Consider hyperbaric oxygen or bisphosphonates in refractory cases 5

Critical Pitfalls to Avoid

• Do NOT delay biopsy waiting for laboratory results—histopathology distinguishes vasculitis from thrombosis and determines treatment urgency 8, 1
• Do NOT order hypercoagulability panels during acute anticoagulation or acute illness—results will be falsely abnormal and mislead management 4
• Do NOT continue warfarin or heparin if drug-induced necrosis is suspected—immediate cessation with specific antidotes is required to prevent progression 1, 3
• Do NOT assume retiform purpura is pyoderma gangrenosum—hypercoagulability is the most common mimicker, and immunosuppression without anticoagulation worsens outcomes 4
• Do NOT delay vasculitis treatment for biopsy confirmation if clinical suspicion is high and patient is critically ill—mortality increases with delayed glucocorticoid and immunosuppressive therapy 8
• Do NOT use ANCA titers to guide treatment changes—structured clinical assessment should inform treatment decisions, not serial ANCA levels 8

Follow-Up and Monitoring

• Vasculitis patients: Manage at or in close collaboration with centers of expertise; assess for relapse and treatment-related complications (infection, cardiovascular risk) every 3-6 months 8
• Anticoagulated patients: Monitor INR weekly until stable, then monthly; assess for bleeding complications 1
• Calciphylaxis patients: Weekly wound assessment and calcium-phosphate monitoring during sodium thiosulfate therapy 5
• All patients: Repeat biopsy if new lesions develop or treatment fails, as this may indicate alternative diagnosis or disease evolution 1, 2